cancer testing News
-
IONIQ Sciences is awarded “Best of Salt Lake City – Cancer Testing 2021”
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) is honored to announce it has been awarded “Best of Salt Lake City – Cancer Testing 2021.” We are humbled to have our mission to modernize early-stage cancer detection continue to be recognized nationally and locally. Through our novel application of bioimpedance technology, we believe that we’re ...
-
miR Scientific Presents Groundbreaking Data on the Exceptional Accuracy of its Prostate Cancer Liquid-Biopsy Test
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...
-
IONIQ Receives Three Awards including ‘Best Medical Technology Company 2022’
IONIQ Sciences is humbled to be recognized with three separate awards from ‘Global 100‘ especially during ‘Lung Cancer Hope Month.’ These three awards and earlier designation by the US FDA as a ‘Breakthrough Device‘ is further validation of our growing clinical evidence library from seven trials at 24 sites with 1.2K subjects and more than 20M data points. ...
-
Rocío Arroyo, CEO of Amadix, has been chosen as one of the protagonists of change in 2022 in the list made by Forbes.
This year, the specialized magazine has selected 22 people, including Rocío Arroyo, who stand out for their talent, leadership, productivity, and power to change the world. Rocío Arroyo has been distinguished by her professional career as scientific, researcher and entrepreneur in the oncologic field with the development of early cancer detection tests by Amadix. Read the ...
By Amadix
-
miR Scientific and Leonie Hill Capital Announce Collaboration to Introduce Breakthrough Urine Liquid Biopsy Prostate Cancer Test in Singapore
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
-
ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC). The ...
-
E.ON signs Luxembourg Declaration on Workplace Health Promotion
At the full conference of its works councils in Berlin on 5 November 2009, E.ON AG signed the Luxembourg Declaration on Workplace Health Promotion in the European Union for its entire Group. The company is thus committed to applying the principles of workplace health promotion (WHP) throughout the Group and is continuing its occupational safety and health practices in accordance with the ...
By E.ON AG
-
EPA places four IRIS assessments on hold pending review (HQ)
The U.S. Environmental Protection Agency (EPA) announced today that it is holding four of its ongoing IRIS (Integrated Risk Information System) assessments pending a review of some of the underlying studies used in the assessments. EPA conducts IRIS assessments to determine the impact of specific chemicals on human health. EPA is holding these assessments due to a report from the National ...
-
Canadian Government-Sponsored Collaboration Targets Standardized Cancer Testing
Genome Canada, the Ontario Institute for Cancer Research (OICR) and Thermo Fisher Scientific are collaborating to develop a complete solution of targeted next generation sequencing (NGS) assays and analysis software designed to more effectively assess – and eventually improve management of – pancreatic, prostate and breast cancer. The $6 million, three-year initiative aims to ...
-
Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
-
miR Scientific to Present the Prostate Cancer Application of its Liquid Biopsy miR Disease Management Platform® at the 12th Annual Prostate Cancer Awareness Day (PCAD) at the Massachusetts State House
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced today that its Chairman & CEO, Sam Salman, will be virtually presenting at the 12th Annual Prostate Cancer Awareness Day at the Massachusetts State House ...
-
Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests
Partnership will Make Guardant Health Cancer Tests Available to Over 250 Million Patients with a Record in Epic Integration Will Simplify the Process for Clinicians to Order Tests and Access Results Directly in the Patient Record REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with Epic, the ...
-
Biomark Announces Closing of $1,5 Million Financing Round to Accelerate Commercialization of Its Liquid Biopsy Technology
BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed a financing round to accelerate the commercialization of its liquid biopsy technology. The financing round included a non-brokered private ...
-
miR Scientific launches "Can do Blue" on September 1, 2022, as Prostate Cancer Awareness Month
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
-
Israel Ministry of Health Expands Testing Coverage for Non-Small Cell Lung Cancer Patients
Starting this month, comprehensive molecular profiling is now covered for patients with non-small cell lung cancer (NSCLC) in Israel, as outlined in a letter from the Israeli Ministry of Health to medical directors of the country’s health insurance funds. According to the letter, every NSCLC patient in the country is eligible for comprehensive molecular profiling as part of the expansion of ...
-
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
-
EPA announces plan of action to address four iris assessments
The U.S. Environmental Protection Agency (EPA) announced today its plan to address the four draft Integrated Risk Information System (IRIS) assessments that were placed on hold in June 2010, pending a review of some of the underlying studies relied on in the assessments. EPA conducts IRIS assessments to determine the potential impact of specific chemicals on people’s health. The four ...
-
miR Scientific is proud to announce the commercial availability of the miR Sentinel™ Prostate Cancer Test
NEW YORK, July 13, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets. miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA using a proprietary biostatistical algorithm. The miR Sentinel™ Test assesses the ...
-
Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData´s 700 Market Analysts
World markets are constantly changing and developing. To stay aligned with the latest trends and events, companies now need a global business intelligence provider that can predict where an industry is headed next, so that they can adapt, react and evolve. Global Information Inc (GII), in partnership with market research publisher GlobalData, offer decision makers and executives integrated ...
-
Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM – May 19, 2022 – – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDX program, has finalized a foundational Local Coverage Determination (LCD) for Molecular Biomarkers to ...
By MDxHealth
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you